Form 4: CG Oncology Director Acquires Stock Options
SEC Form 4 Filing
Leonard E. Post, a director of CG Oncology, Inc., acquired stock options for 15,600 shares of common stock on October 4, 2024.
Summary
- On October 4, 2024, Leonard E. Post, a director of CG Oncology, Inc., acquired stock options.
- The options grant the right to buy 15,600 shares of CG Oncology's common stock at an exercise price of $36.63 per share.
- The options vest monthly over a year, starting October 4, 2024, contingent upon continuous service to the Issuer.
- The options expire on October 3, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of stock options by a director can be seen as a mildly positive signal, but it's not a major event.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule of the options is contingent upon the director's continued service to the company.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 10/04/2024 | Date of the transaction (grant of stock options) and start of vesting period. |
| 10/03/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.